Core Viewpoint - The company expects to achieve a profit of no less than RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1] Group 1: Financial Performance - The company anticipates a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to decrease by about 8% to 12% compared to a gross profit of approximately RMB 184 million for the six months ending June 30, 2024 [1] Group 2: Revenue Decline Factors - The anticipated revenue decline is mainly due to a reduction in content service revenue, as some clients are shifting to direct marketing strategies, reducing their reliance on Real World Evidence (RWS) support services [2] - The decrease in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure leading to reduced income from comprehensive healthcare service packages [2] - Digital marketing service revenue is also expected to decline due to economic downturns prompting clients to cut advertising and marketing expenditures [2]